nivolumab
bms
['nivo', 'gi ']
 patients with ibd have a 41% risk of gi irae compared to 11% in non ibd controls said dr michael dougan, md, phd. treating patients with autoimmune diseases remains challenging. excellent aim-nivo investigator s meeting #asco22 
Assistant Professor of Investigational Cancer Therapeutics @MDAndersonNews. Specializing in early phase #clinicaltrials. Tweets are my own.